that BAPN can inhibit fibrosis chemotherapeutically; this toxic reaction has been shown to be advantageous in the treatment of pulmonary silicosis in rats. It is hoped that further work will lead to a compound having a therapeutic effect in man in decreasing deleterious fibrosis.
Professor F Beck (University of Leicester) discussed teratogenesis produced by drugs and related compounds and stressed the dangers existing in the use of rigid, unvarying test systems. The production of neoplasia during drug therapy was described by Professor T A Connors (MRC Toxicology Unit, Carshalton). The metabolic production of reactive species important in iatrogenic cancer was discussed together with recent evidence which suggests that patients treated with certain cytotoxic agents have an increased probability of developing neoplasia.
The series of lectures concluded with a paper by Dr D H Keeling (Plymouth General Hospital), who discussed the many side effects associated with the use of radiopharmaceuticals and emphasized the need for stricter control in the handling and production of reactive sources used in radiotherapy.
Attendance at this school by scientists from all over the United Kingdom and Europe gives an indication of the mounting interest in problems of drug toxicity. The lectures are being published early in 1979 (Aspects of Drug Toxicity, edited by J W Gorrod. Taylor & Francis, London).
J T MARSDEN

Chelsea College, University of London
Cancer chemotherapy: successes, failures and hopes
Successes, failures and hopes in cancer chemotherapy was the theme of an international symposium 1 organized by the Medico-Pharmaceutical Forum at the end of May 1978. In opening the Symposium Professor G Mathe (Paris) spoke of the alternating moods of optimism and pessimism which have characterized work in the cancer field. The need was to maintain the momentum of recent years and the symposium aimed to bring together academic and pharmaceutical interests, to review what had been achieved and to rook at some of the new developments.
To put the present place of chemotherapy into perspective Professor N M Bleehen (Cambridge) emphasized what, by unwritten Transatlantic agreement, has come to be known as the multimodality approach. It is the simple common sense of using surgery, radiotherapy and chemotherapy together to achieve the best total effect. In looking to the future it is appropriate to keep the door open for developments in immunology, dietary manipulation, hyperthermia and unconventional methods, provided they can be demonstrated to be unequivocally effective.
Surgery is generally considered to be fully exploited but the question how much further radiotherapy can be extended presents an interesting challenge through the development of radiosensitizing drugs which have a powerful electron affinity and exert their main effects on radioresistant hypoxic cells. Dr K E Halnan (Glasgow) reviewed this development and preliminary clinical studies are beginning to appear, but it is still too early to assess the potential of even the first drugs available for clinical trial.
Professor H G Schwick (Marburg) outlined the difficulties encountered in attempting to manipulate host immunological activity, but we are further on the road to understanding these problems now than we were a few years ago, when numerous attempts were being made to translate inadequate immunological knowledge into immunotherapeutic procedures; it seems clear that the prospects for successful immunological manipulation depend on unravelling the highly complex mechanisms involved.
The fact that chemotherapy is so far effective for only a small range of malignancies is partly compensated by the fact that sensitive tumours occur predominantly in young adults and children.
Professor J M A Whitehouse (Southampton) reviewed their main area of impact, the acute lymphoblastic leukaemias and Hodgkin's disease, together with their less prolonged benefits for patients with the acute myeloblastic leukaemias and non-Hodgkin's lymphoma. Although children's cancer accounts for only I~o of all tumours, cancer now comes second only to accidents as a cause of death in childhood. The treatment of Wilms' tumour, rhabdomyosarcoma and some brain tumours by multiple modality approach is one of the areas of success and Dr J S Malpas (St Bartholomew's Hospital) drew attention to the need to have drugs which could be used without long-term toxicity on heart, lungs, liver and kidneys, and which did not incur the risk of second primary tumours.
In the adult solid tumour field reviewed by Dr E S Newlands (Charing Cross Hospital) the major successes had been few, although temporary con-© 1979 The Royal Societyof Medicine trol even in the area of oat cell carcinoma of the bronchus was becoming less elusive. The value of good markers, which had contributed to the suc-. cessful treatment of gestational trophoblastic tumours, was now demonstrable with malignant teratomas of ovary, testes and mediastinum, and remarkable progress was being made in their treatment. The successful use of chemotherapy for micrometastases following surgery for osteosarcoma was emerging, but it had not been proved that the same approach was effective in breast cancer.
The reasons why some tumours respond and others do not respond to chemotherapy, and why some respond initially but then become resistant, remain a major challenge. Some of the known mechanisms of drug resistance were described by Professor M Ghione (Milan), and it is clear that the problems spill over from the area of pharmacology and drug metabolism into biochemistry and cell kinetics. In any clinical situation we still have little or no idea of the causes of either success or failure.
There are a number of potential methods of improving the specificity of delivery of cytotoxic agents to tumour cells. Professor B E Ryman (Charing Cross Hospital) described studies of liposomes in which cytotoxic agents are encased in a lipid layer of variable constitution, size and electric charge. They can be labelled to indicate their distribution both in experimental animals and in man, and although adequate homing of liposomes in human tumours has not been demonstrated, the potential of this approach is by no means fully explored.
One of the approaches to producing new cytotoxic agents arises from the study of different classes of existing drugs and this was exemplified by Dr S Crooke (Syracuse). He showed the relationships between various cytotoxic polypeptides, including bleomycin, tallisomycin, neocalcinostatin and macromycin, and indicated what could be inferred about their properties from their structures. Similarly Dr J K Luce (Wilmington) described studies relating to adriamycin and its analogues and attempts to increase their efficacy by reducing cardiac toxicity. Dr T A Connors (Carshalton) reviewed a wider range of cytotoxic chemicals and the potential for analogues in each class of compound to extend existing capabilities. At a more clinical level Dr S J Carter (Palo Alto) reviewed the patterns of activity of the newer agents coming into clinical use and undergoing evaluation.
From amongst a vast number of drugs one or two penetrate the elaborate preclinical screens each year and emerge into clinical practice. On this basis alone we can expect the range of effective chemotherapy to be steadily, if not dramatically, exten-ded. The type of drug which emerges is thought by many to be restricted by present screening programmes largely to inhibitors of DNA replication. If damage to DNA were the only property of these drugs it is unlikely that they would do more than have toxic effects on normal cell renewal tissues such as bone marrow and gut epithelium. Fortunately, they do have some secondary discriminatory characteristics which result in relative sparing of one or more of these cell renewal tissues. It is these secondary characteristics which the clinician exploits, so that some tumour cell populations, numbering 101°_1011 cells, can be effectively eliminated despite the fact that an estimated 10 12 normal tissue cells are generated each day in the adult. Even with these relatively crude agents, then, a remarkable degree of discrimination can already be achieved, if only for a few tumours.
There is, it seems, no shortage of new approaches to more selective cancer chemotherapy. We often hear the cry that we have to wait to find the real difference between the cancer and the normal cell. The fact is that there are already many biochemical differences defined to distinguish certain cancers from the generality of normal cells. Surprisingly, there has so far appeared to be little attempt to exploit these differences, and one can only speculate why this is so. Perhaps with the use of anti-oestrogens in carcinoma of the breast, we are at the beginning of attempts to exploit welldefined chemical receptors present only in certain classes of cell. It is this type of approach which ultimately appears to hold prospects for more selective agents. Doubt of course remains about whether all the cells in a tumour population express the particular characteristic, or whether eradication will always have to depend on multiple methods of attack.
One of the trends emerging from established therapy is that each type of cancer seems to require a 'tailor-made' approach. Specificagents for specific types of therapy are perhaps less attractive to the pharmacological chemist than more universal agents. Also, the differences between cancer and normal cells emerge in the fields of molecular and cell biology and biochemistry, and the relevance of this to the development of new drugs may seem obscure or tenuous. However, attempts need to be made, although the problems are unlikely to be solved on a short time-scale. Academic institutions have not proved to have the capability of the pharmaceutical industry to produce useful drugs, and the difficulties of bridge building between diverse disciplines may be formidable, but surely they are not insurmountable.
